Supporting treatment adherence and directly observed therapy
What it is
Individual case management with directly observed therapy (DOT) is preferred for all patients to ensure adherence and prevent emergence of drug resistance. DOT is treatment supervised by a healthcare professional or family member, where the person is observed swallowing their medication to improve adherence; dosing frequency may be reduced to three times a week to make DOT more convenient. Poor adherence is a major factor in prolonged illness, risk of relapse, and the emergence of drug resistance.
The criteria for implementing it are patients thought unlikely to comply, whether from a history of serious mental illness or a history of non-adherence to TB therapy in the past or during the current treatment course; homeless people; and multi-drug resistant TB.
It is not a step beside the antituberculous regimen but part of it: how often the drugs may be given depends on whether the doses are being observed.
How it is treated
The regimen it belongs to has two phases: an intensive phase of two months, followed by a continuation phase of four to seven months. Two effective drugs should be used at all times, and in the initial phase, the first 2 months, at least three effective drugs are recommended. Treatment should be guided by the results of drug sensitivity testing.
Dosing frequency is where DOT changes what is allowed:
- Daily in the intensive phase and daily in the continuation phase is the optimal dosing frequency.
- Daily in the intensive phase with 3 times weekly in the continuation phase is an acceptable alternative for any new patient receiving directly observed therapy.
- 3 times weekly in both phases is an acceptable alternative, provided that the patient is receiving directly observed therapy and is not living with HIV or living in an HIV-prevalent setting.
Daily rather than 3 times weekly intensive-phase dosing may help to prevent acquired drug resistance in patients starting treatment with isoniazid resistance.